Kura Oncology, Inc.

Kura Oncology, Inc. is a U.S.-based biopharmaceutical company focused on precision medicines for cancer, with a pipeline built around small-molecule therapies that target cancer signaling pathways. The company evolved from a research-stage developer into a commercial-stage oncology business after FDA approval of ziftomenib, marketed as KOMZIFTI, for relapsed or refractory NPM1-mutated AML.

−448,4 %

−412,9 %

+25,2 %

6.06

6.05

— Kura Oncology, Inc.
%
Commercial oncology product3% Approved and marketed cancer therapy sold in the United States under the KOMZIFTI brand.
Clinical-stage oncology pipeline72% Investigational small-molecule programs targeting AML, GIST and other solid tumors.
Collaboration and license revenue25% Upfront, milestone and service revenue from the Kyowa Kirin partnership.

Kura sells KOMZIFTI through specialty distributors and specialty pharmacies in the United States, which then supply...

  • Specialty distributors and specialty pharmaciesprimary

    They purchase KOMZIFTI in the U.S. and resell it to providers and patients, making them the direct commercial channel.

  • Oncology physicians and treatment centersprimary

    Hematologists and oncologists choose whether to use KOMZIFTI or trial combinations in AML and other cancers.

  • Third-party payorsprimary

    Commercial and government payors determine coverage, prior authorization and patient access, which directly affects adoption.

  • Kyowa Kirinsecondary

    The collaboration partner provides funding, services and commercial support under the license agreement.

  • Clinical trial investigators and research sitessecondary

    Academic and community sites enroll patients in ziftomenib and other pipeline studies to advance approvals.

Kura is headquartered in the United States and generates product revenue from U.S. sales of KOMZIFTI...

  • •United States is the only disclosed product revenue market for KOMZIFTI
  • •U.S. commercialization depends on specialty pharmacy and distributor access
  • •Europe, China and Japan are relevant for patent protection and future expansion
  • •Clinical development is global in scope through trials and IP filings
  • •Kyowa Kirin partnership adds cross-border collaboration exposure

Kura’s strategy is to build KOMZIFTI into the anchor commercial product while expanding ziftomenib across the AML...

01
Commercialize KOMZIFTI in U.S. AMLshort-term

The approved product is the first source of product revenue and the base for future oncology franchise growth.

02
Expand ziftomenib into frontline AMLmedium-term

Frontline AML is a larger market than relapsed/refractory disease and could materially expand the addressable patient pool.

03
Broaden the pipeline beyond AMLmedium-term

Additional indications reduce dependence on a single asset and create optionality if AML competition intensifies.

04
Maintain financing flexibilityshort-term

The company remains cash-consuming and needs capital to fund trials, launch activities and manufacturing scale-up.

Kura remains highly dependent on ziftomenib, so clinical, regulatory or commercial setbacks could materially impair the...

high

Dependence on ziftomenib success

The company’s value creation is concentrated in one lead asset across multiple indications.

Scope
AML and future ziftomenib indications
Materiality
high
high

Clinical and regulatory failure

Product candidates must succeed in registrational trials and obtain FDA approval before commercialization.

Scope
Frontline AML, GIST and other pipeline programs
Materiality
high
high

Competitive pressure in oncology

Large pharma and biotech competitors may launch faster, be safer or more effective, reducing market share.

Scope
AML and targeted oncology markets
Materiality
high
high

Financing risk

The company has a history of operating losses and needs substantial funding for trials and commercialization.

Scope
Corporate liquidity and pipeline funding
Materiality
high
medium

Reimbursement and access risk

Coverage decisions and prior authorization can slow adoption of a newly launched specialty drug.

Scope
U.S. KOMZIFTI sales
Materiality
high
Net product revenue estimation
Affects reported product revenue and gross-to-net deductions
Collaboration and license revenue recognition
Can create uneven quarterly revenue recognition
Clinical trial accruals
Can shift expense recognition between periods
Commercial launch reserves
May affect margins and near-term earnings volatility

INCYTE CORP

INCY · Services-Commercial Physical & Biological Research

OnKure Therapeutics, Inc.

OKUR · Pharmaceutical Preparations

Kymera Therapeutics, Inc.

KYMR · Biological Products, (No Diagnostic Substances)

Karyopharm Therapeutics Inc.

KPTI · Pharmaceutical Preparations

Cogent Biosciences, Inc.

COGT · Pharmaceutical Preparations

Cardiff Oncology, Inc.

CRDF · Biological Products, (No Diagnostic Substances)

: 28/04/2026